Form 4: Ligand Pharmaceuticals CFO Sells Shares in Open Market Transaction

Ligand Pharmaceuticals' Chief Financial Officer, Octavio Espinoza, sold 2,104 shares of common stock at a weighted average price of $116.3738 on December 23, 2024.

Summary

• Octavio Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals, sold 2,104 shares of the company's common stock on December 23, 2024.
• The shares were sold at a weighted average price of $116.3738 per share.
• The sale was executed in multiple transactions with prices ranging from $116.33 to $116.71.
• Following the transaction, Mr. Espinoza directly owns 20,647 shares of Ligand Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of a stock sale by an executive, which is a routine event. It does not indicate any positive or negative sentiment.

Industry Context

This is a routine disclosure of an insider transaction, which is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for all publicly listed companies, including those in the pharmaceutical sector.
• The sale of shares by a CFO is not unusual and can be for various personal financial reasons.
• Comparable companies would also have similar filings when their executives trade company stock.

Stakeholder Impact

• The sale of shares by a company executive may have a minor impact on shareholder sentiment, but is generally considered a normal part of market activity.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, insider trading, stock sale, Octavio Espinoza, CFO, executive transaction